Topics
News
CME/CE
Editorial Advisory Board
Partners
Subscribe
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
Article
Psoriasis study provides important insight into anti-inflammatory mechanism of TNF blockade
Results from a clinical study investigating the in situ mechanism of action of etanercept (Enbrel, Amgen) in the treatment of psoriasis indicate this agent, which binds both tumor necrosis factor (TNF) and lymphotoxin, breaks the cycle of dendritic cell activation and maturation and thereby decreases T-cell activation and the production of a cascade of inflammatory mediators by multiple cell types, Alice B. Gottlieb, M.D., Ph.D., says.
Related Videos
Related Content
